Metronidazole, omeprazole and clarithromycin: an effective combination therapy for Helicobacter pylori infection. 1995

M M Yousfi, and H M el-Zimaity, and M T al-Assi, and R A Cole, and R M Genta, and D Y Graham
Department of Medicine, Veterans Affairs Medical Center, Houston, TX 77030, USA.

BACKGROUND Successful treatment of Helicobacter pylori infection results in cure of peptic ulcer disease. Multi-drug regimens are needed to cure this infection. We studied the effectiveness and side effect profile of two antibiotics active against Helicobacter pylori, metronidazole and clarithromycin, combined with omeprazole. METHODS We evaluated a combination therapy for H. pylori infection consisting of metronidazole (500 mg b.d.), omeprazole (20 mg b.d.), and clarithromycin (250 mg b.d.) for 2 weeks, followed by ranitidine 300 mg daily for 4 weeks. RESULTS Thirty-three patients with documented H. pylori infection were studied. Twenty had previously failed antimicrobial therapy, including one with metronidazole-based triple therapy and eight with macrolide-based therapy (five with clarithromycin-based therapy), and 11 with amoxycillin, tetracycline, and bismuth. H. pylori status was determined by histopathology using the Genta stain and by culture. H. pylori status was determined at entry and 4 weeks after completing antimicrobial therapy. The H. pylori infection was cured in 88% (95% CI = 72%-96%) including 90% of those who had failed previous anti-H. pylori therapies. Mild side effects were reported by 18%. CONCLUSIONS We conclude that the combination of metronidazole, omeprazole and clarithromycin is an effective treatment for H. pylori infection.

UI MeSH Term Description Entries
D008297 Male Males
D008795 Metronidazole A nitroimidazole used to treat AMEBIASIS; VAGINITIS; TRICHOMONAS INFECTIONS; GIARDIASIS; ANAEROBIC BACTERIA; and TREPONEMAL INFECTIONS. 2-Methyl-5-nitroimidazole-1-ethanol,Bayer 5360,Clont,Danizol,Flagyl,Gineflavir,Metric,MetroGel,Metrodzhil,Metrogyl,Metronidazole Hydrochloride,Metronidazole Monohydrochloride,Metronidazole Phosphate,Metronidazole Phosphoester,Satric,Trichazol,Trichopol,Trivazol,Vagilen,2 Methyl 5 nitroimidazole 1 ethanol
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009853 Omeprazole A 4-methoxy-3,5-dimethylpyridyl, 5-methoxybenzimidazole derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits an H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS. H 168-68,Omeprazole Magnesium,Omeprazole Sodium,Prilosec,H 168 68,H 16868,Magnesium, Omeprazole,Sodium, Omeprazole
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D005260 Female Females
D005500 Follow-Up Studies Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease. Followup Studies,Follow Up Studies,Follow-Up Study,Followup Study,Studies, Follow-Up,Studies, Followup,Study, Follow-Up,Study, Followup
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly

Related Publications

M M Yousfi, and H M el-Zimaity, and M T al-Assi, and R A Cole, and R M Genta, and D Y Graham
December 1996, Zhonghua nei ke za zhi,
M M Yousfi, and H M el-Zimaity, and M T al-Assi, and R A Cole, and R M Genta, and D Y Graham
January 1998, Digestion,
M M Yousfi, and H M el-Zimaity, and M T al-Assi, and R A Cole, and R M Genta, and D Y Graham
March 1998, Helicobacter,
M M Yousfi, and H M el-Zimaity, and M T al-Assi, and R A Cole, and R M Genta, and D Y Graham
February 2002, Nihon rinsho. Japanese journal of clinical medicine,
M M Yousfi, and H M el-Zimaity, and M T al-Assi, and R A Cole, and R M Genta, and D Y Graham
October 1995, Zeitschrift fur Gastroenterologie,
M M Yousfi, and H M el-Zimaity, and M T al-Assi, and R A Cole, and R M Genta, and D Y Graham
January 2000, Canadian journal of gastroenterology = Journal canadien de gastroenterologie,
M M Yousfi, and H M el-Zimaity, and M T al-Assi, and R A Cole, and R M Genta, and D Y Graham
June 1996, The Medical letter on drugs and therapeutics,
M M Yousfi, and H M el-Zimaity, and M T al-Assi, and R A Cole, and R M Genta, and D Y Graham
July 1992, Lancet (London, England),
M M Yousfi, and H M el-Zimaity, and M T al-Assi, and R A Cole, and R M Genta, and D Y Graham
April 1996, Alimentary pharmacology & therapeutics,
M M Yousfi, and H M el-Zimaity, and M T al-Assi, and R A Cole, and R M Genta, and D Y Graham
October 1998, Journal of pediatric gastroenterology and nutrition,
Copied contents to your clipboard!